Daily news email for February 10, 2012 | Click here for updated news
Biotechnology - Moreover Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
NIH Translational Center Should Raise All Boats, BIO Says
Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
Biotechnology to be 21st-century industry: Life Tech CEO
|
Burrill Report Americans Warming to Healthcare Reform Law
E-Prescriptions Could Improve Patient Adherence
Drug Supplies and Economics 101
Big Pharma Declares War on Neglected Diseases
Two Life Sciences IPOs Debut Below Target
|
CenterWatch - Clinical Trials Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
Technology companies adapt interactive video concepts for clinical trial informed consent
CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
|
New York Times- Pharmaceuticals Killer Meds, Warring Feds
Exemestane, Thought to Prevent Cancer, Also Causes Bone Loss
Children’s A.D.D. Drugs Don’t Work Long-Term
Army Studies Workout Supplements After 2 Deaths
Pfizer and Eli Lilly, Squeezed by Generics, Top Forecasts
|
OnBioVC Functional Neuromodulation, Inc.: Series A $10.4M
Uptake Medical, Inc.: Series C $35M
Topica Pharmaceuticals, Inc.: Series B $27M
GenoLogics, Inc.: Series D $8M
Courtagen Life Sciences, Inc.: Series B $8M
|
Outsourcing-Pharma An experienced CMO is key to successful biologics development says Cobra Biologics
Parexel discusses transdermal drug delivery techs
Sponsors and CROs differ on perception of service quality, says the Avoca Group
Recipharm CEO talks CMO sector recovery and Asian plans
Covance adding mass spec for biosimilars
|